The Geneva Foundation

The Geneva Foundation, a 501(c)(3) nonprofit research organization headquartered in Tacoma, Washington, delivers biomedical research, clinical trial execution, and medical research support services to the Department of Defense and federal health agencies as a prime contractor (86% of recent awards) and occasional subcontractor. The foundation competes full-and-open with no set-aside designations across its prime footprint, deriving its federal customer base primarily from defense health research missions.

The Defense Health Agency and Department of the Army Medical Command dominate the foundation's customer concentration, together accounting for 344 awards (51% of the recent prime portfolio) with combined potential value of $96.6 million. The National Institute of Allergy and Infectious Diseases ranks third by potential value at $109.1 million across 22 awards, followed by the Department of the Navy Bureau of Medicine and Surgery at $69.5 million across nine awards. This concentration—with the top five customers representing 92% of combined potential value—reflects the foundation's specialization in military medical research priorities rather than civilian-sector diversification.

The foundation's concrete capability portfolio centers on advanced biomedical research addressing combat casualty care, infectious disease, orthopedic and musculoskeletal rehabilitation, blast injury mitigation, and cancer immunotherapy. Representative prime work includes a $561,042 Air Force contract with the Metis Foundation as subcontractor to study therapeutic effects of NVG-291 on blast-induced hearing loss (completed September 2026); a $4.397 million Defense Health Agency grant to research extracorporeal immunomodulation for severe burns and sepsis (through October 2028); a $4.82 million Defense Health Agency grant for patient-matched orthopedic implant system development with mechanobiologic activation and antimicrobial coating (through July 2028); and a $2.816 million Uniformed Services University cooperative agreement supporting sleep physiology modeling under the ARPA H BIG REST initiative (through August 2031). The foundation also holds a $999,146 Other Transaction IDV with the Defense Advanced Research Projects Agency for low-intensity focused ultrasound modulation of deep brain structures to enhance REM sleep, though no task orders have been issued to date.

On federal grants, the foundation acts as prime recipient on 86% of its award portfolio, with the Defense Health Agency and Uniformed Services University dominating the pipeline. The foundation serves as recipient under the Military Medical Research and Development program (CFDA 12.420) and the Uniformed Services University Medical Research Projects program (CFDA 12.750), with award volumes of approximately 30 per year across FY2022–FY2024, declining to 21 in FY2026 year-to-date. Recent grant awards span three- to five-year performance periods addressing cancer immunotherapy (CAR T-cell development for breast cancer, pancreatic cancer microbiota research, prostate cancer genomics), diagnostic innovation (near-infrared hematoma imaging for intracranial hemorrhage, concussion diagnostic devices), musculoskeletal rehabilitation (blood transfusion optimization, lower back pain intervention research), infectious disease vaccine development (malaria multivalent approaches, dengue durability studies), and neurological research (sleep physiology, traumatic brain injury biomarkers, blast overpressure exposure effects).

The foundation frequently sub-awards to academic medical centers and research universities, with named sub-recipients including the Henry M. Jackson Foundation for the Advancement of Military Medicine (appearing across blood transfusion optimization, orthopedic outcomes research, and immunological studies), the Uniformed Services University, Johns Hopkins University, Emory University, University of Pittsburgh, Vanderbilt University Medical Center, and others. The foundation also engages as a named subcontractor to primes including Teledyne Scientific & Imaging (on wearable neurotechnology for insomnia treatment under a Combat Readiness Research Program award), the Medical College of Wisconsin (on mild traumatic brain injury biomarker studies), Battelle Memorial Institute (on vaccine evaluation), Kitware (on DARPA triage challenge and AI/moral language model work), and Serco (on holistic health and fitness program support).

The foundation holds positions on two primary Army-managed indefinite delivery contracts: the W81XWH11D0049 IDIQ with 60 task orders (combined potential value $36.4 million) and the W911QY16A0014 BPA with 35 task orders ($6.3 million combined potential value). Activity trajectory shows growth from 30 awards in FY2022 to a peak of 49 in FY2024, followed by 38 in FY2025 and 21 in FY2026 year-to-date; the decline in FY2026 reflects partial-year coverage through September 30, 2026. The recompete cliff is modest: 39 awards carrying combined potential value of $1 million reach ultimate completion within the next twenty-four months.

SCI-reported invoicing on federal service contracts above the $150,000 threshold totaled $1.2 million across FY2024–FY2025 (FY2024: $454 thousand, FY2025: $788 thousand), with the foundation delivering roughly 2.7 FTEs per fiscal year on captured prime contracts, absent meaningful subcontractor hour share. On the foundation's GSA Multiple Award Schedule (held under 38 active labor categories), hourly rates range from $41.14 to $168.25, spanning administrative assistants at entry level through research pharmacists at the top; median government-paid rates on SCI-reportable contracts run around $75.53 per hour, with senior labor (epidemiologists, program managers, postdoctoral fellows) pricing through $121–$168 per hour. The foundation offers no security-cleared positions on the GSA Schedule and does not carry defense contracting vehicles such as SEWP or Alliant.